About ZemairaWhat is Alpha-1?Patient SupportPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Could it be Alpha-1?Alpha-1 Versus COPDAssessment QuestionaireQuestions to ask your doctorReceive Zemaira at no charge for up to 2 weeks.

Could it be Alpha-1?

Do you have a chronic breathing problem that isn’t responding to treatment? You could have a serious genetic condition called Alpha-1 (also known as alpha-1 antitrypsin, or AAT) deficiency.

  • Up to 95% of people with Alpha-1 don’t even know they have it1
  • Yet 2% to 3% of emphysema patients (40,000 to 60,000 people) could have Alpha-11

In a survey of 300 Alpha-1 patients, 44% visited at least 3 different doctors before receiving a diagnosis of Alpha-1 and the interval between the appearance of symptoms and their diagnosis with Alpha-1 was 7.2 years.2 Yet Alpha-1 can be detected with a relatively simple blood test, with a doctor confirming the diagnosis.

Talk to your doctor about Alpha-1 testing today if you have any of the following:1

  • Chronic obstructive pulmonary disease (COPD), emphysema, or chronic bronchitis
  • Asthma that does not respond well to treatment
  • Unexplained liver disease
  • A family history of Alpha-1

As part of its ongoing commitment to the Alpha-1 community, CSL Behring has developed a comprehensive Alpha-1 Detection Program to help educate healthcare professionals on the need for Alpha-1 testing and how to test, diagnose, and treat Alpha-1 deficiency. Learn more about this program and be proactive—print a copy of the page for your doctor and help us support this important initiative.

An early diagnosis of Alpha-1 benefits you and your family. Members of your family can be tested to determine if they, too, have this genetic condition.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  1. American Thoracic Society/European Respiratory Society Task Force. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003; 168:818-900.
  2. Stoller JK. α1-antitrypsin deficiency. Thorax. 2004;59(2):92-93.